Drotrecogin alfa (activated) is a recombinant form of human activated protein C
that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a
recombinant form of human activated protein C. It was approved by the Food ...
Oct 25, 2011 ... October 25, 2011 — Eli Lilly is withdrawing activated drotrecogin alfa (Xigris), a
drug intended to treat severe sepsis in high-risk patients, from ...
In November 2001, the Food and Drug Administration (FDA) approved
drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high
risk of ...
Description, Drotrecogin alfa is activated human protein C that is synthesized by
recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton ...
Learn about drug side effects and interactions for the drug Xigris (Drotrecogin
Sep 1, 2009 ... Xigris (drotrecogin alfa (activated)) is a recombinant form of human activated
protein C. An established human cell line possessing the ...
Drotrecogin alfa [recombinant Human Activated Protein C (Xigris™)], was
recently approved by the FDA for the reduction of mortality in adult patients with
Drug information on Xigris (drotrecogin alfa), includes drug pictures, side effects,
drug interactions, directions for use, symptoms of overdose, and what to avoid.
Sep 22, 2004 ... On 25 October 2011, Eli Lilly and Company announced the withdrawal of its
Xigris (drotrecogin alfa [activated]) product in all markets following ...